Nektar Therapeutics Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Nektar Therapeutics (NKTR) Misses Q1 EPS by 7c, Revenues Beat
May 7, 2020 6:19 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.78), $0.07 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $50.57 million versus the consensus estimate of $47.64 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More